We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Immunovaccine Licenses Clinical Stage Cancer Vaccine from Merck KGaA

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Immunovaccine Licenses Clinical Stage Cancer Vaccine from Merck KGaA"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
Immunovaccine Inc. announced that it has signed an agreement with Merck KGaA of Darmstadt, Germany, to in-license EMD 640744, an investigational therapeutic survivin-based cancer vaccine designed to target multiple solid tumors and hematological malignancies.

Immunovaccine will build on the current on-going Phase 1 study for EMD 640744 by formulating the survivin-based vaccine in its DepoVax™ delivery system. It is envisioned that after some preclinical work, the EMD 640744-DepoVax combination vaccine will proceed quickly into Phases 1 and 2 of clinical development.

The license agreement grants Immunovaccine exclusive worldwide rights, under issued patents and patent applications, to develop and commercialize the survivin-based vaccine for multiple cancer indications. Under the terms, Immunovaccine will pay Merck KGaA success-based milestones and royalties as a percentage of product sales. Further financial terms were not disclosed.

"Merck KGaA is a global leader with a track record of successfully developing therapies for cancer and we are excited to be working with them on such a vaccine candidate. We look forward to expediting the clinical development of this EMD 640744-DepoVax combination, and expanding Immunovaccine's vaccine pipeline," said Dr. Randal Chase, President and CEO of Immunovaccine Inc.